Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1409

Postherpetic Neuralgia Therapeutics (PHN) - Pipeline Assessment and Market Forecasts to 2017

Postherpetic Neuralgia Therapeutics (PHN) - Pipeline Assessment and Market Forecasts to 2017

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $2,000.00
Meta Description Postherpetic Neuralgia Therapeutics (PHN) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry
Publisher GlobalData
Date of Report Jun 15, 2011
Quick Overview
Postherpetic Neuralgia Therapeutics (PHN) - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Postherpetic Neuralgia Therapeutics (PHN) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Postherpetic Neuralgia Therapeutics market. The report identifies the key trends shaping and driving the global Postherpetic Neuralgia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Postherpetic Neuralgia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Postherpetic Neuralgia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postherpetic Neuralgia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Postherpetic Neuralgia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Postherpetic Neuralgia Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Postherpetic Neuralgia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Postherpetic Neuralgia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Postherpetic Neuralgia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Postherpetic Neuralgia Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Postherpetic Neuralgia Therapeutics: Introduction 7
2.1 Overview 7
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 7
2.4 Symptoms 8
2.5 Diagnosis 8
2.6 Treatment and Management Pattern 8
2.7 GlobalData Pipeline Report Guidance 10
3 Postherpetic Neuralgia Therapeutics: Market Characterization 11
3.1 Postherpetic Neuralgia Therapeutics Market Size (2005-2010) - Global 11
3.2 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017) - Global 12
3.3 Postherpetic Neuralgia Therapeutics Market Size (2005-2010): The US 13
3.4 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): The US 14
3.5 Postherpetic Neuralgia Therapeutics Market (2005-2010): France 15
3.6 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): France 16
3.7 Postherpetic Neuralgia Therapeutics Market (2005-2010): Germany 17
3.8 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Germany 18
3.9 Postherpetic Neuralgia Therapeutics Market (2005-2010): Italy 19
3.10 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Italy 20
3.11 Postherpetic Neuralgia Therapeutics Market (2005-2010): Spain 21
3.12 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Spain 22
3.13 Postherpetic Neuralgia Therapeutics Market (2005-2010): The UK 23
3.14 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): The UK 24
3.15 Postherpetic Neuralgia Therapeutics Market (2005-2010): Japan 25
3.16 Postherpetic Neuralgia Therapeutics Market Forecast (2010-2017): Japan 26
3.17 Drivers and Barriers for the Postherpetic Neuralgia Therapeutics Market 27
3.17.1 Drivers for the Postherpetic Neuralgia Therapeutics Market 27
3.17.2 Barriers for the Postherpetic Neuralgia Therapeutics Market 27
3.18 Opportunity and Unmet Need Analysis 28
3.19 Key Takeaway 28
4 Postherpetic Neuralgia Therapeutics: Competitive Assessment 29
4.1 Overview 29
4.2 Strategic Competitor Assessment 29
4.3 Product Profile for the Major Marketed Products in the Postherpetic Neuralgia Therapeutics Market 30
4.3.1 Lidoderm (lidocaine patch 5%) 30
4.3.2 Neurontin (gabapentin) 31
4.3.3 Lyrica (pregabalin) 32
4.3.4 Qutenza (capsaicin 8% patch) 34
4.3.5 Gralise (gabapentin) 35
4.4 Key Takeaway 35
5 Postherpetic Neuralgia Therapeutics: Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Postherpetic Neuralgia Therapeutics Pipeline – Pipeline by Phases of Development 36
5.3.1 Postherpetic Neuralgia Therapeutics – Phase III Pipeline 37
5.3.2 Postherpetic Neuralgia Therapeutics – Phase II Pipeline 37
5.3.3 Postherpetic Neuralgia Therapeutics – Preclinical Pipeline 37
5.4 Postherpetic Neuralgia Therapeutics Market – Clinical Pipeline by Mechanism of Action 38
5.5 Technology Trends Analytical Framework 39
6 Postherpetic Neuralgia Therapeutics: Clinical Trials Mapping 41
6.1 Clinical Trials by Country (US, EU5 & Japan) 41
6.2 Clinical Trials by Phase 42
6.3 Clinical Trials by Trial Status 43
6.4 Prominent Sponsors 44
6.5 Key Companies Participating in Therapeutics Clinical Trials 46
7 Postherpetic Neuralgia Therapeutics: Stategic Assessment 47
7.1 Key Events Impacting on the Future Market 47
7.2 Postherpetic Neuralgia Therapeutics: Implications for Future Market Competition 48
8 Postherpetic Neuralgia Therapeutics: Future Players 49
8.1 Introduction 49
8.2 Company Profiles 50
8.2.1 Pfizer Inc. 50
8.2.2 Bial Group 52
8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.: 53
8.2.4 Adolor Corp. 54
8.2.5 Allergan Inc.: 55
8.2.6 GlaxoSmithKline Plc 57
8.2.7 Durect Corp. 59
8.2.8 EpiCept Corporation 61
8.2.9 Xenon Pharmaceuticals Inc. 62
8.2.10 KAI Pharmaceuticals Inc. 63
8.2.11 Other Companies in the Postherpetic Neuralgia Therapeutics Market 63
9 Postherpetic Neuralgia Therapeutics: Licensing and Partnership Deals 65
10 Postherpetic Neuralgia Therapeutics: Appendix 67
10.1 Market Definitions 67
10.2 Abbreviations 67
10.2.1 Methodology 68
10.2.2 Coverage 68
10.2.3 Secondary Research 69
10.2.4 Forecasting 69
10.2.5 Primary Research 72
10.2.6 Expert Panels 72
10.3 Contact Us 72
10.4 Disclaimer 72
10.5 Bibliography 73




...